Blood and Marrow Transplant State of the Science Symposium

描述(由申请人提供)： 这项建议寻求支持将于2007年6月26-27日在密歇根州安娜堡举办的造血细胞移植(HCT)“科学现状”研讨会。每年有数以千计的人接受HCT治疗恶性和非恶性疾病。目前估计全球每年的HCT数量约为45,000例，美国每年约为15-20,000例。增加使用的原因包括已证实的和潜在的对许多疾病的疗效，对适当的时机和患者选择的更好的了解，更多的捐赠者和更好的确定人类白细胞抗原配型的技术，更容易的干细胞采集，以及更好的支持性护理。尽管有了这些改进，但HCT的应用仍然受到发病率和死亡率相对较高的风险的限制，对于异基因HCT来说，缺乏合适的捐赠者。2001年，国家心肺血液研究所(NHLBI)和国家癌症研究所(NCI)共同建立了血液和骨髓移植临床试验网络(BMT CTN)。该网络的首要目标是进行临床试验，明确回答当前HCT医疗实践中的关键问题，通过在多中心环境下评估新的HCT方法和管理策略来改善患者结果。这次研讨会的目的是确定BMT CTN在未来五年内可以启动的最引人注目的临床研究机会，并在BMT和血液学科学界传播其结论。这个 2000年举行的第一次专题讨论会的建议指导了BMT CTN头五年的科学议程，我们期望第二次专题讨论会的建议也同样重要。BMT CTN领导层已经成立了12个委员会，以评估翻译和临床HCT研究的最新进展，并已获得该领域12位杰出领导人的同意，担任委员会主席。重要的是，我们打算公布研讨会的建议，并计划在2007年ASH会议和2008年串联会议上口头介绍研讨会的主要发现。

DESCRIPTION (provided by applicant): This proposal seeks support for the organization of a "State of the Science" Symposium in Hematopoietic Cell Transplantation (HCT) to be held in Ann Arbor, Michigan on June 26-27, 2007. Thousands of HCTs are performed to treat malignant and non-malignant diseases each year. Current estimates of annual numbers of HCTs are about 45,000 worldwide, with 15-20,000 annually in the United States. Reasons for increasing use include proven and potential efficacy in many diseases, better understanding of appropriate timing and patient selection, greater availability of donors and better techniques for determining HLA match, greater ease of stem cell collection, and improved supportive care. Despite these improvements, application of HCT is still limited by relatively high risks of morbidity and mortality and, in the case of allogeneic HCT, availability of suitable donors. In 2001, The National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) jointly established a Blood and Marrow Transplant Clinical Trials Network (BMT CTN). The network's overarching goal is to conduct clinical trials that will definitively answer key questions in current HCT medical practice that can improve patient outcomes by assessing novel HCT methods and management strategies in a multi-center setting. The purpose of this symposium is to identify the most compelling clinical research opportunities that can be initiated in the next five years by the BMT CTN, and to disseminate its conclusions among the BMT and Hematology scientific communities. The recommendations of the first symposium, held in 2000, guided the scientific agenda of the BMT CTN during its first five years, and we expect the second symposium's recommendations to be equally important. The BMT CTN leadership has already formed twelve committees to evaluate recent advances in translational and clinical HCT research, and has received agreement from twelve distinguished leaders in the field to act as committee chairpersons. Importantly, we intend to publish the recommendations of the symposium and we plan oral presentations of the symposium's major findings at the 2007 ASH meeting and the 2008 Tandem meeting.